ArticleBiological psychiatry2025
Neural Signatures of Bipolar Disorder and Psychotropic Medication Effects: A Multimodal Positron Emission Tomography-Magnetic Resonance Imaging Study.
Article in Biological psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundSynaptic loss and altered network function in frontolimbic brain regions have been implicated in the neurobiology of bipolar disorder (BD), but in vivo evidence remains limited. Synaptic vesicle glycoprotein 2A (SV2A), a biomarker of synaptic density, can be quantified using [
methodsNineteen individuals with BD, including BDI (n = 13) and BDII (n = 6), and healthy control (HC) participants (n = 26) completed SV2A PET imaging in parallel with structural and functional magnetic resonance imaging to assess frontolimbic synaptic density, gray matter volume (GMV), and intrinsic connectivity, respectively.
resultsIndividuals with BD showed lower frontolimbic SV2A density, which exploratory analyses revealed to be seemingly driven by individuals taking psychotropic medications (BD-med). Conversely, group differences in GMV were observed only when accounting for medication status, with higher GMV in BD-med individuals relative to unmedicated individuals with BD (BD-none). Connectivity was higher in the BD group overall, but lower in the BD-med group relative to the BD-none group. SV2A and GMV were positively correlated in HC participants. However, this relationship was absent in individuals with BD, with lower SV2A/GMV ratios being associated with greater impulsivity in BD.
conclusionsThese findings provide the first in vivo evidence of synaptic deficits in BD and offer preliminary evidence suggesting that psychotropic medications may differentially influence brain structure and function. These results underscore the importance of accounting for medication effects when interpreting neuroimaging findings in BD and the need to disentangle illness-related changes from medication effects on brain and behavior in BD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.